Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Director | March 31, 2026 | April 02, 2026 |
| AbbVie Inc.ABBV · Entity 2800 | Director | March 31, 2026 | April 02, 2026 |
| Tricida, Inc.TCDA · Entity 122050 | Director | November 23, 2022 | November 25, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date March 31, 2026 · Filed April 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Equivalent UnitsSEC Table II · derivative / convertible security | Direct | 10,544 |
Reported balance
After 2026-03-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-31 · Grant · Acquired 76 · Balance 10,544 F1: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. |
Filing footnotes · ownership attribution and instrument terms
F1: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.
F2: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.
AbbVie Inc.
Report date March 31, 2026 · Filed April 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Equivalent UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $217.49 | Direct | 10,369 |
Reported balance
After 2026-03-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-31 · Grant · Acquired 35 · Balance 10,369 F1: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. |
Filing footnotes · ownership attribution and instrument terms
F1: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.
F2: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.
Tricida, Inc.
Report date November 23, 2022 · Filed November 25, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-11-23 transaction · row 1
1 source rowRow 1 · 2022-11-23 · Sale · Disposed 131,879 · Balance 0 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.21 to $0.22, inclusive. The reporting person undertakes to provide to Tricida, Inc., any security holder of Tricida, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.21 to $0.22, inclusive. The reporting person undertakes to provide to Tricida, Inc., any security holder of Tricida, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2026 Filed Apr 2, 2026 21:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 76 | $102.67 | $7,802.92 |
DisclosureSEC source: 0001448074-26-000008 · form4-04022026_090418.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,544 Underlying: Common Shares · 76 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 21:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantStock Equivalent Units · Derivative | 35 | $217.49 Strike: $217.49 | $7,612.15 |
DisclosureSEC source: 0001448074-26-000007 · form4-04022026_050406.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,369 Underlying: Common Stock · 35 shares Expires not disclosed F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 23:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 62 | $125.29 | $7,767.98 |
DisclosureSEC source: 0001448074-26-000004 · form4-01052026_110149.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,409 Underlying: Common Shares · 62 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantStock Equivalent Units · Derivative | 34 | $228.49 Strike: $228.49 | $7,768.66 |
DisclosureSEC source: 0001448074-26-000003 · form4-01052026_050110.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,257 Underlying: Common Stock · 34 shares Expires not disclosed F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 58 | $133.94 | $7,768.52 |
DisclosureSEC source: 0001448074-25-000011 · form4-10022025_081051.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,300 Underlying: Common Shares · 58 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 21:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantStock Equivalent Units · Derivative | 33 | $231.54 Strike: $231.54 | $7,640.82 |
DisclosureSEC source: 0001448074-25-000012 · form4-10022025_051004.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,151 Underlying: Common Stock · 33 shares Expires not disclosed F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| June 30, 2025 Filed Jul 1, 2025 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 57 | $136.01 | $7,752.57 |
DisclosureSEC source: 0001415889-25-018729 · form4-07012025_090737.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,195 Underlying: Common Shares · 57 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 21:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantStock Equivalent Units · Derivative | 40 | $185.62 Strike: $185.62 | $7,424.80 |
DisclosureSEC source: 0001415889-25-019106 · form4-07022025_050704.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,038 Underlying: Common Stock · 40 shares Expires not disclosed F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| May 09, 2025 Filed May 13, 2025 21:05 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 1,203 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-012793 · form4-05132025_050503.xml · nonDerivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,646 F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 25, 2025 Filed Apr 29, 2025 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,635 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011510 · form4-04292025_090442.xml · nonDerivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,798 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 59 | $132.65 | $7,826.35 |
DisclosureSEC source: 0001415889-25-009706 · form4-04022025_090440.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,093 Underlying: Common Shares · 59 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantStock Equivalent Units · Derivative | 35 | $209.52 Strike: $209.52 | $7,333.20 |
DisclosureSEC source: 0001415889-25-009691 · form4-04022025_050412.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,907 Underlying: Common Stock · 35 shares Expires not disclosed F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 22:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 69 | $113.11 | $7,804.59 |
DisclosureSEC source: 0001415889-25-000528 · form4-01032025_100102.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,988 Underlying: Common Shares · 69 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantStock Equivalent Units · Derivative | 42 | $177.70 Strike: $177.70 | $7,463.40 |
DisclosureSEC source: 0001415889-25-000521 · form4-01032025_050107.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,788 Underlying: Common Stock · 42 shares Expires not disclosed F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 21:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 69 | $114.01 | $7,866.69 |
DisclosureSEC source: 0001415889-24-024236 · form4-10012024_091011.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,872 Underlying: Common Shares · 69 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 21:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantStock Equivalent Units · Derivative | 37 | $197.48 Strike: $197.48 | $7,306.76 |
DisclosureSEC source: 0001415889-24-024452 · form4-10022024_051007.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,655 Underlying: Common Stock · 37 shares Expires not disclosed F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| June 30, 2024 Filed Jul 2, 2024 20:22 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 75 | $103.91 | $7,793.25 |
DisclosureSEC source: 0001415889-24-018885 · form4-07022024_080725.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,754 Underlying: Common Shares · 75 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| June 30, 2024 Filed Jul 2, 2024 20:18 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantStock Equivalent Units · Derivative | 43 | $171.52 Strike: $171.52 | $7,375.36 |
DisclosureSEC source: 0000897069-24-001471 · form4.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,541 Underlying: Common Stock · 43 shares Expires not disclosed F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| May 03, 2024 Filed May 7, 2024 22:30 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 1,322 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-012527 · form4-05072024_060528.xml · nonDerivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,443 F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 26, 2024 Filed Apr 30, 2024 21:33 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,866 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-011784 · form4-04302024_090408.xml · nonDerivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,163 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| March 31, 2024 Filed Apr 2, 2024 22:32 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 69 | $113.66 | $7,842.54 |
DisclosureSEC source: 0001415889-24-009860 · form4-04022024_100416.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,628 Underlying: Common Shares · 69 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| March 31, 2024 Filed Apr 2, 2024 21:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantStock Equivalent Units · Derivative | 41 | $182.10 Strike: $182.10 | $7,466.10 |
DisclosureSEC source: 0001415889-24-009802 · form4-04022024_050408.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,408 Underlying: Common Stock · 41 shares Expires not disclosed F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| December 31, 2023 Filed Jan 3, 2024 22:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 71 | $110.07 | $7,814.97 |
DisclosureSEC source: 0001415889-24-000359 · form4-01032024_100123.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,512 Underlying: Common Shares · 71 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| December 31, 2023 Filed Jan 3, 2024 22:08 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantStock Equivalent Units · Derivative | 48 | $154.97 Strike: $154.97 | $7,438.56 |
DisclosureSEC source: 0001415889-24-000335 · form4-01032024_100107.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,285 Underlying: Common Stock · 48 shares Expires not disclosed F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 30, 2023 Filed Oct 3, 2023 22:45 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 81 | $96.85 | $7,844.85 |
DisclosureSEC source: 0001415889-23-013947 · form4-10032023_101054.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,392 Underlying: Common Shares · 81 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 30, 2023 Filed Oct 3, 2023 21:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantStock Equivalent Units · Derivative | 50 | $149.06 Strike: $149.06 | $7,453.00 |
DisclosureSEC source: 0001415889-23-013895 · form4-10032023_051001.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,139 Underlying: Common Stock · 50 shares Expires not disclosed F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 07, 2023 Filed Sep 11, 2023 21:00 UTC | AbbVie Inc. ABBV · Entity 2800 | OtherCommon Stock, $0.01 par value | 129 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-013148 · form4-09112023_050901.xml · nonDerivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,121 Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 15:54 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 72 | $109.02 | $7,849.44 |
DisclosureSEC source: 0001104659-23-077918 · tm2320556-1_4seq1.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,266 Underlying: Common Shares · 72 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 21:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantStock Equivalent Units · Derivative | 55 | $134.73 Strike: $134.73 | $7,410.15 |
DisclosureSEC source: 0001415889-23-010773 · form4-07052023_050701.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,001 Underlying: Common Stock · 55 shares Expires not disclosed F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| May 05, 2023 Filed May 9, 2023 21:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 1,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-007664 · form4-05092023_050502.xml · nonDerivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,992 F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 28, 2023 Filed May 2, 2023 23:37 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-007126 · form4-05022023_110558.xml · nonDerivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,297 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 23:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 77 | $101.26 | $7,797.02 |
DisclosureSEC source: 0001415889-23-006148 · form4-04042023_110402.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,151 Underlying: Common Shares · 77 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 21:00 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantStock Equivalent Units · Derivative | 47 | $159.37 Strike: $159.37 | $7,490.39 |
DisclosureSEC source: 0001415889-23-006074 · form4-04042023_050406.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,856 Underlying: Common Stock · 47 shares Expires not disclosed F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| December 31, 2022 Filed Jan 4, 2023 23:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 71 | $109.79 | $7,795.09 |
DisclosureSEC source: 0001415889-23-000426 · form4-01042023_110134.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,030 Underlying: Common Shares · 71 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| December 31, 2022 Filed Jan 3, 2023 22:06 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantStock Equivalent Units · Derivative | 46 | $161.61 Strike: $161.61 | $7,434.06 |
DisclosureSEC source: 0001415889-23-000087 · form4-01032023_100102.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,723 Underlying: Common Stock · 46 shares Expires not disclosed F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F3 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| November 23, 2022 Filed Nov 25, 2022 21:13 UTC | Tricida, Inc. TCDA · Entity 122050 | SaleCommon Stock | 131,879 | $0.21 | $27,694.59 |
DisclosureSEC source: 0001595585-22-000093 · wf-form4_166941082049026.xml · nonDerivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.21 to $0.22, inclusive. The reporting person undertakes to provide to Tricida, Inc., any security holder of Tricida, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| November 21, 2022 Filed Nov 23, 2022 01:33 UTC | Tricida, Inc. TCDA · Entity 122050 | SaleCommon Stock | 27,584 | $0.23 | $6,344.32 |
DisclosureSEC source: 0001595585-22-000091 · wf-form4_166916716773671.xml · nonDerivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,879 Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 21:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 81 | $96.76 | $7,837.56 |
DisclosureSEC source: 0001415889-22-010261 · form4-10042022_021033.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,918 Underlying: Common Shares · 81 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 21:02 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantStock Equivalent Units · Derivative | 55 | $134.21 Strike: $134.21 | $7,381.55 |
DisclosureSEC source: 0001415889-22-010242 · form4-10042022_021018.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,598 Underlying: Common Stock · 55 shares Expires not disclosed F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 20:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 72 | $108.65 | $7,822.80 |
DisclosureSEC source: 0001415889-22-007169 · form4-07012022_010708.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,800 Underlying: Common Shares · 72 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 21:25 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantStock Equivalent Units · Derivative | 47 | $153.16 Strike: $153.16 | $7,198.52 |
DisclosureSEC source: 0001415889-22-007380 · form4-07052022_020740.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,458 Underlying: Common Stock · 47 shares Expires not disclosed F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 20:34 UTC | Tricida, Inc. TCDA · Entity 122050 | GrantStock Option (right to buy) · Derivative | 27,207 | $0.00 Strike: $9.87 | $0.00 |
DisclosureSEC source: 0001595585-22-000057 · wf-form4_165541165921267.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,207 Underlying: Common Stock · 27,207 shares Expires 2032-06-14 F1 · derivative.exercise_date: Subject to the Reporting Person's continuous service to the Issuer as a non-employee director through each vesting date, this option vests ratably on a monthly basis, on the monthly anniversary of June 15, 2022 ("Option Date"), over the one-year period following the Option Date so that the option shall be 100% vested and exercisable on the one-year anniversary of the Option Date ("Vesting Date"); provided, however, if the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Option Date (the "Next Annual Meeting") occurs prior to the Vesting Date, then the option shall vest in full one day prior to the Next Annual Meeting. Read SEC document |
| May 06, 2022 Filed May 9, 2022 21:09 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 1,421 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-002924 · edgar.xml · nonDerivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,542 F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 29, 2022 Filed May 3, 2022 21:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,602 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-004546 · form4-05032022_020514.xml · nonDerivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,481 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 21:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 66 | $118.36 | $7,811.76 |
DisclosureSEC source: 0001415889-22-003587 · form4-04012022_020455.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,690 Underlying: Common Shares · 66 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 21:14 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantStock Equivalent Units · Derivative | 44 | $162.11 Strike: $162.11 | $7,132.84 |
DisclosureSEC source: 0001179110-22-002544 · edgar.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,335 Underlying: Common Stock · 44 shares Expires not disclosed F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 22:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 55 | $140.74 | $7,740.70 |
DisclosureSEC source: 0001415889-22-000228 · form4-01042022_020147.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,591 Underlying: Common Shares · 55 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 22:02 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantStock Equivalent Units · Derivative | 53 | $135.40 Strike: $135.40 | $7,176.20 |
DisclosureSEC source: 0001179110-22-000118 · edgar.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,210 Underlying: Common Stock · 53 shares Expires not disclosed F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 21:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 66 | $118.13 | $7,796.58 |
DisclosureSEC source: 0001415889-21-004707 · form4-10042021_021007.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,505 Underlying: Common Shares · 66 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 21:04 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantStock Equivalent Units · Derivative | 66 | $107.87 Strike: $107.87 | $7,119.42 |
DisclosureSEC source: 0001179110-21-009160 · edgar.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,068 Underlying: Common Stock · 66 shares Expires not disclosed F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.